Low-dose chemo or hormone pill: which helps advanced cancer patients live longer without progression?

NCT ID NCT00420563

Completed Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Mar 22, 2026 · Last updated May 18, 2026 · Updated 6 times

Summary

This study tested two treatments for people with advanced cancer who had no other options. One group received a low-dose chemotherapy pill (cyclophosphamide) taken daily, and the other group received a hormone pill (megestrol). The main goal was to see how many patients in each group were alive without their cancer getting worse after 2 months. The study enrolled 88 adults with various cancers (except breast cancer) and good physical condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Centre Hospitalier Regional - Dermatology

Lille, 59035, France
Centre Hospitalier Regional - Oncology

Lille, 59035, France
Centre Oscar Lambret

Lille, 59020, France
Hopital Saint Vincent

Lille, 59020, France

Conditions

Explore the condition pages connected to this study.

CANCER